YHO-13177 is a selective and potent inhibitor of BCRP, it potentiates the cytotoxicity of SN-38 in cancer cells and has no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Breast cancer resistance protein (BCRP) is a member of the ATP-binding cassette (ABC) transporter superfamily that regulates drug resistance. YHO-13177 is a novel acrylonitrile derivative that has been shown to reverse BCRP-mediated drug resistance both in vitro and in vivo. In BCRP-transduced HCT116 cells, treatment with YHO-13177 at 0.01-1 μM reversed the drug resistance to BCRP substrates (SN-38, topotecan, and mitoxantrone) in a dose-dependent manner, while it showed no effect on the drug sensitivity of parental HCT116 cells expressing no BCRP. YHO-13177 at the concentrations of 0.01-1 μM also reversed the drug resistance in A549 cells with BCRP-mediated acquired resistance to SN-38. The cytotoxicity of SN-38 in cells that intrinsically express BCRP (RPMI-8226, NCI-H23, NCI-H460, and AsPC-1 cell lines) was significantly potentiated by YHO-13177 at 0.01-1 μM. Treatment with YHO-13177 (0.1 to 10 μM) significantly induced the intracellular accumulation of Hoechst 33342 in both A549/SN4 and HCT116/BCRP cells. YHO-13177 from 0.01-1 μM partially suppressed the expression of BCRP protein in both A549/SN4 and HCT116/BCRP cells without affecting the mRNA expression of BCRP. In mice inoculated with BCRP-transduced murine leukemia P388 cells, the combined treatment of irinotecan (i.v., 45 mg/kg) and YHO-13351 (p.o., 50, 100, or 200 mg/kg), a prodrug of YHO-13177, significantly enhanced the survival time of mice in a dose-dependent manner[2]. |
作用机制 | YHO-13177 is a novel acrylonitrile derivative that reverses the drug resistance and enhances the cytotoxicity of anticancer drugs in BCRP-expressing cancer cells and xenografts by inhibiting the drug transport function and the posttranscriptional expression of BCRP. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.70mL 0.54mL 0.27mL |
13.50mL 2.70mL 1.35mL |
26.99mL 5.40mL 2.70mL |
CAS号 | 912287-56-0 |
分子式 | C20H22N2O3S |
分子量 | 370.465 |
别名 | |
运输 | 蓝冰 |
存储条件 |
粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 35 mg/mL(94.48 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |